1. Design and synthesis of novel site-specific antibody-drug conjugates that target TROP2.
- Author
-
Luo C, Ren A, Jin Z, Zhang J, Shi W, Zeng Y, Liu Z, Lu M, Hou Y, Tang F, and Huang W
- Subjects
- Humans, Animals, Mice, Female, Molecular Structure, Drug Screening Assays, Antitumor, Structure-Activity Relationship, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Cell Line, Tumor, Antibodies, Monoclonal, Humanized chemistry, Antibodies, Monoclonal, Humanized pharmacology, Oligopeptides, Immunoconjugates chemistry, Immunoconjugates pharmacology, Antigens, Neoplasm immunology, Antigens, Neoplasm metabolism, Drug Design, Cell Adhesion Molecules antagonists & inhibitors, Cell Adhesion Molecules metabolism, Cell Adhesion Molecules immunology, Antineoplastic Agents chemistry, Antineoplastic Agents chemical synthesis, Antineoplastic Agents pharmacology
- Abstract
The approval of Trodelvy® validates TROP2 as a druggable but challenging target for antibody-drug conjugates (ADCs) to treat metastatic triple-negative breast cancer (mTNBC). Here, based on the TROP2-targeted antibody sacituzumab, we designed and developed several site-specific ADC candidates, which employ MMAE (monomethyl auristatin E) as the toxin, via IgG glycoengineering or affinity-directed traceless conjugation. Systematic evaluation of these site-specific ADCs in homogeneity, hydrophilicity, stability, and antitumor efficiency was conducted. The results indicate that the site-specific ADCs gsADC 3b made from one-step glycoengineering exhibit good aggregation stability and in vivo efficacy, providing a new format of ADCs that target TROP2., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF